Boundless Bio, Inc. (BOLD) vs INmune Bio, Inc. (INMB)

Boundless Bio, Inc. and INmune Bio, Inc. are both Biotechnology companies. Boundless Bio, Inc. and INmune Bio, Inc. are of similar size ($59.1M and $55.5M). Across the 9 metrics below, Boundless Bio, Inc. leads on 6 and INmune Bio, Inc. on 3.

Valuation

Metric BOLD INMB Biotechnology median
P/E n/m n/m 7.88
P/S n/m 401.77 11.47
P/B 0.91 2.66 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 301.47 10.73
Earnings yield (107.52%) (33.00%) (28.84%)
Free cash flow yield (95.00%) (30.30%) (23.03%)

Profitability

Metric BOLD INMB Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (67.86%) (74.82%) (57.72%)
Return on assets (50.56%) (57.08%) (49.22%)
Return on invested capital 0.00% (646.94%) 0.00%

Growth

Metric BOLD INMB Biotechnology median
Revenue growth (TTM) — (51.61%) 5.64%
EPS growth (last fiscal year) 32.47% 11.85% —
Revenue growth, 5-year CAGR — 35.37% 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BOLD INMB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 9.48 4.04 4.73
Net debt to EBITDA 0.99 0.52 0.96

Dividend

Metric BOLD INMB Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric BOLD INMB Biotechnology median
Market cap 59.14m 55.51m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack